Septem 20gust 20simple
Sword 20red 20orange 20trans 20 5bsmall 5d

Sword Diagnostics

Sword’s core intellectual property enables the company to provide Pharma with Build-to-Order tests that meet their exact needs in a matter of weeks.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Chicago, IL, US
  • Currency USD
  • Founded April 2005
  • Employees 13
  • Incorporation Type C-corp
  • Website sworddx.com

Company Summary

Sword’s patented technology enables rapid production of "Build-to-Order" tests that speed drug development and seamlessly integrate with 50-year-old technology in use today. Our tests do not require changes to test instruments or protocols. Customers include BMS, Eli Lilly, Novartis, TEVA and Sanofi Genzyme, with drug development efforts targeting many diseases. Sword has Master Services Agreements with its first two large pharma companies.

Team

  • Default avatar
    Gail Page
    Executive Chair

    Ms. Page is a diagnostics industry veteran with over 25 years executive experience, including commercialization, business development and general management of leading companies who are among Sword’s target customers. Former Executive Vice President and Chief Operating Officer of Luminex Corporation. Ms. Page also held senior level management positions, member and chair of the Scientific Advisory Board, Labcorp.

  • Dc1d548e 426d 409b 83f5 8ae02b08c19e
    President and CEO

    Mr. Dingott is a Fortune-10 trained business leader with 30 years’ experience identifying, creating and leading businesses from proof of concept to successful commercial enterprise. Mr. Dingott served as Director of many new diverse product and service-based businesses, growing them from concept to commercial enterprises.

  • 0c4fa273 044c 4222 9ee4 4e8da6a8729d
    Chief Science Officer

    Mr. Kundu has over 20 Years of Leadership in the Abbott Laboratories Medical Diagnostics Division. His research and dedication has resulted in:
    35 patents (15 U.S. Patents and 25 International Patents)
    65 publications (in books and journal)
    10+ Technical Reports
    Self-published Books: “Recent Advances in Immunoassays” and “Guidance to Cleaning Validation in Diagnostics” at Amazon

  • Default avatar
    Rob Donoho
    VP, Sales & Marketing

    Mr. Donoho has 15+ years of experience in Strategy Development & Executive for early stage life sciences companies. Focusing on profit-driven technology solutions for the life sciences market, Mr. Donoho brings his in-depth knowledge and network of Pharmaceutical and Biotechnology clients and their processes. His previous positions include Head of Market Development, Roche Diagnostics.

Advisors

  • Default avatar
    Mary Beth Kerrigan - Morse, Barnes-Brown, & Pendleton, PC, Waltham, MA
    Lawyer
    Unconfirmed
    Default avatar
    Ted Hollander, CPA - Complus Inc., Chicago, IL
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    NJTC Ventures
    Unconfirmed
    Default avatar
    Keiretsu Forum
    Unconfirmed
    Default avatar
    Calvert Group
    Unconfirmed
  • Default avatar
    Heartland Angels
    Unconfirmed
    Default avatar
    Elevate Ventures
    Unconfirmed
    Default avatar
    Ellipsis Ventures
    Unconfirmed